Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.

DiSano KD, Royce DB, Gilli F, Pachner AR.

Front Immunol. 2019 Aug 2;10:1821. doi: 10.3389/fimmu.2019.01821. eCollection 2019.

2.

Differential neuro-immune patterns in two clinically relevant murine models of multiple sclerosis.

DiSano KD, Linzey MR, Royce DB, Pachner AR, Gilli F.

J Neuroinflammation. 2019 May 22;16(1):109. doi: 10.1186/s12974-019-1501-9.

3.

Clinical utility of a molecular signature in inflammatory demyelinating disease.

Pachner AR, DiSano K, Royce DB, Gilli F.

Neurol Neuroimmunol Neuroinflamm. 2018 Nov 9;6(1):e520. doi: 10.1212/NXI.0000000000000520. eCollection 2019 Jan.

4.

Critical analysis of a doxycycline treatment trial of rhesus macaques infected with Borrelia burgdorferi.

Wormser GP, O'Connell S, Pachner AR, Schwartz I, Shapiro ED, Stanek G, Strle F.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):183-188. doi: 10.1016/j.diagmicrobio.2018.06.007. Epub 2018 Jun 18.

PMID:
30017315
5.

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.

Gilli F, De La Torre AL, Royce DB, Pachner AR.

Int Immunopharmacol. 2018 Sep;62:1-6. doi: 10.1016/j.intimp.2018.06.030. Epub 2018 Jun 27.

PMID:
29960044
6.

Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.

Gilli F, Royce DB, DiSano KD, Pachner AR.

J Neuroimmunol. 2017 Dec 15;313:34-40. doi: 10.1016/j.jneuroim.2017.10.004. Epub 2017 Oct 9.

PMID:
29153606
7.

Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Gilli F, Li L, Royce DB, DiSano KD, Pachner AR.

J Neurovirol. 2017 Dec;23(6):825-838. doi: 10.1007/s13365-017-0570-8. Epub 2017 Sep 14.

PMID:
28913765
8.

Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease.

Jiang Y, Patel CD, Manivanh R, North B, Backes IM, Posner DA, Gilli F, Pachner AR, Nguyen LN, Leib DA.

MBio. 2017 Jul 5;8(4). pii: e00678-17. doi: 10.1128/mBio.00678-17.

9.

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis.

Gilli F, Royce DB, Pachner AR.

J Vis Exp. 2016 Nov 14;(117). doi: 10.3791/54616.

10.

High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.

Gilli F, Chen X, Pachner AR, Gimi B.

PLoS One. 2016 Jul 28;11(7):e0160071. doi: 10.1371/journal.pone.0160071. eCollection 2016.

11.

The effect of B-cell depletion in the Theiler's model of multiple sclerosis.

Gilli F, Li L, Campbell SJ, Anthony DC, Pachner AR.

J Neurol Sci. 2015 Dec 15;359(1-2):40-7. doi: 10.1016/j.jns.2015.10.012. Epub 2015 Oct 8.

PMID:
26671084
12.

The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

Gilli F, Li L, Pachner AR.

J Neurovirol. 2016 Feb;22(1):66-79. doi: 10.1007/s13365-015-0369-4. Epub 2015 Aug 11.

PMID:
26260496
13.

Chemokine biomarkers in central nervous system tissue and cerebrospinal fluid in the Theiler's virus model mirror those in multiple sclerosis.

Pachner AR, Li L, Gilli F.

Cytokine. 2015 Dec;76(2):577-580. doi: 10.1016/j.cyto.2015.06.010. Epub 2015 Jun 30.

PMID:
26141421
14.

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.

Lane MA, Renga V, Pachner AR, Cohen JA.

Case Rep Neurol Med. 2015;2015:892047. doi: 10.1155/2015/892047. Epub 2015 Jan 29.

15.

Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.

Wormser GP, Baker PJ, O'Connell S, Pachner AR, Schwartz I, Shapiro ED.

Vector Borne Zoonotic Dis. 2012 Jul;12(7):535-8. doi: 10.1089/vbz.2012.1012. Epub 2012 May 23. Review.

16.

A second case of Marburg's variant of multiple sclerosis with vasculitis and extensive demyelination.

Elenein RG, Sharer LR, Cook SD, Pachner AR, Michaels J, Hillen ME.

Mult Scler. 2011 Dec;17(12):1531-8. doi: 10.1177/1352458511414042. Epub 2011 Aug 3.

PMID:
21816761
17.

The effect of FTY720 in the Theiler's virus model of multiple sclerosis.

Li L, Matsumoto M, Seabrook TJ, Cojean C, Brinkman V, Pachner AR.

J Neurol Sci. 2011 Sep 15;308(1-2):41-8. doi: 10.1016/j.jns.2011.06.029. Epub 2011 Jul 2.

PMID:
21726878
18.

Experimental models of multiple sclerosis.

Pachner AR.

Curr Opin Neurol. 2011 Jun;24(3):291-9. doi: 10.1097/WCO.0b013e328346c226. Review.

PMID:
21519255
19.

Plasma cells in the central nervous system in the Theiler's virus model of multiple sclerosis.

Pachner AR, Li L, Lagunoff D.

J Neuroimmunol. 2011 Mar;232(1-2):35-40. doi: 10.1016/j.jneuroim.2010.09.026. Epub 2010 Oct 20.

PMID:
20961623
20.

Do we need to broaden the spectrum of Lyme neuroborreliosis?

Pachner AR.

J Neurol Sci. 2010 Aug 15;295(1-2):8-9. doi: 10.1016/j.jns.2010.05.007. Epub 2010 Jun 8. No abstract available.

PMID:
20621799
21.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
22.

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators.

Neurology. 2009 Nov 3;73(18):1493-500. doi: 10.1212/WNL.0b013e3181bf98db. Erratum in: Neurology. 2010 Mar 16;74(11):936.

PMID:
19884577
23.

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J.

Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919.

PMID:
19884576
24.

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

PMID:
19279320
25.

The multiple sclerosis severity score (MSSS) predicts disease severity over time.

Pachner AR, Steiner I.

J Neurol Sci. 2009 Mar 15;278(1-2):66-70. doi: 10.1016/j.jns.2008.11.020. Epub 2009 Jan 12.

PMID:
19138773
26.

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.

Pachner AR, Brady J, Steiner I, Narayan K.

J Neurol. 2008 Nov;255(11):1815-7. doi: 10.1007/s00415-008-0854-2. Epub 2008 Nov 22. No abstract available.

PMID:
19031099
27.

Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist.

Pachner AR.

J Neuroimmunol. 2008 Feb;194(1-2):5-6. Epub 2007 Nov 26. No abstract available.

PMID:
18031830
28.

Neutralizing anti-IFNbeta antibodies: clarity and confusion.

Pachner AR.

Mult Scler. 2007 Nov;13(9):1081-2. No abstract available.

PMID:
17967835
29.

The neurotropic herpes viruses: herpes simplex and varicella-zoster.

Steiner I, Kennedy PG, Pachner AR.

Lancet Neurol. 2007 Nov;6(11):1015-28. Review.

PMID:
17945155
31.
32.

Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" story.

Freedman MS, Pachner AR.

Neurology. 2007 Oct 2;69(14):1386-7. No abstract available.

PMID:
17909150
33.

Lyme neuroborreliosis: infection, immunity, and inflammation.

Pachner AR, Steiner I.

Lancet Neurol. 2007 Jun;6(6):544-52. Review.

PMID:
17509489
34.

Intrathecal antibody production in an animal model of multiple sclerosis.

Pachner AR, Li L, Narayan K.

J Neuroimmunol. 2007 Apr;185(1-2):57-63. Epub 2007 Mar 6.

PMID:
17343922
35.

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients.

Pachner AR, Narayan K, Pak E.

Neurology. 2006 Feb 14;66(3):444-6.

PMID:
16476953
36.

Intrathecal antibody production in a mouse model of Lyme neuroborreliosis.

Li L, Narayan K, Pak E, Pachner AR.

J Neuroimmunol. 2006 Apr;173(1-2):56-68. Epub 2006 Jan 4.

PMID:
16387369
37.

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

Pachner AR, Dail D, Pak E, Narayan K.

J Neuroimmunol. 2005 Sep;166(1-2):180-8.

PMID:
16005084
38.

Expression of Borrelia burgdorferi erp genes during infection of non-human primates.

Miller JC, Narayan K, Stevenson B, Pachner AR.

Microb Pathog. 2005 Jul-Aug;39(1-2):27-33.

PMID:
15964737
39.

Defining the spectrum of Lyme disease: a difficult proposition.

Pachner AR.

J Neuroophthalmol. 2005 Jun;25(2):67-8. No abstract available.

PMID:
15937424
40.

The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis.

Narayan K, Dail D, Li L, Cadavid D, Amrute S, Fitzgerald-Bocarsly P, Pachner AR.

Ann Neurol. 2005 Jun;57(6):813-23.

PMID:
15929033
41.

The Therapy of Lyme Neuroborreliosis.

Pachner AR.

Curr Treat Options Neurol. 2005 Mar;7(2):167-170.

PMID:
15676120
42.

Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi.

Cadavid D, Bai Y, Hodzic E, Narayan K, Barthold SW, Pachner AR.

Lab Invest. 2004 Nov;84(11):1439-50.

43.

Genotype determines phenotype in experimental Lyme borreliosis.

Pachner AR, Dail D, Bai Y, Sondey M, Pak L, Narayan K, Cadavid D.

Ann Neurol. 2004 Sep;56(3):361-70.

PMID:
15349863
44.

Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope.

Pachner AR.

J Neuroimmunol. 2004 Jul;152(1-2):vii-viii. No abstract available.

PMID:
15223253
45.

Spinal cord involvement in the nonhuman primate model of Lyme disease.

Bai Y, Narayan K, Dail D, Sondey M, Hodzic E, Barthold SW, Pachner AR, Cadavid D.

Lab Invest. 2004 Feb;84(2):160-72.

46.

Borrelia burgdorferi transcriptome in the central nervous system of non-human primates.

Narasimhan S, Caimano MJ, Liang FT, Santiago F, Laskowski M, Philipp MT, Pachner AR, Radolf JD, Fikrig E.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15953-8. Epub 2003 Dec 11. Erratum in: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1426. Camaino MJ [corrected to Caimano MJ].

47.
48.

Infection and inflammation in skeletal muscle from nonhuman primates infected with different genospecies of the Lyme disease spirochete Borrelia burgdorferi.

Cadavid D, Bai Y, Dail D, Hurd M, Narayan K, Hodzic E, Barthold SW, Pachner AR.

Infect Immun. 2003 Dec;71(12):7087-98.

49.

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

Pachner AR, Bertolotto A, Deisenhammer F.

Neurology. 2003 Nov 11;61(9 Suppl 5):S24-6. Review.

PMID:
14610107
50.

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.

Pachner AR, Oger J, Palace J.

Neurology. 2003 Nov 11;61(9 Suppl 5):S18-20. No abstract available.

PMID:
14610105

Supplemental Content

Loading ...
Support Center